Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice : ANALUTS study
Morote Robles, Juan (Hospital Universitari Vall d'Hebron)
Gomez-Caamaño, Antonio (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
de Celis, Raúl Poza (Hospital Txagorritxu HUA)
Gómez-Veiga, Francisco (Complejo Hospitalario Universitario de A Coruña)
Ciria, Juan P. (Hospital de Donostia (Sant Sebastià, País Basc))
Calleja, Jesús (Hospital Clínico Universitario de Valladolid)
Extramiana, Javier (Hospital Txagorritxu HUA)
Pérez-Sampietro, Maria (Ipsen Pharma)
Perrot, Valerie (Ipsen Pharma)
Angulo, Javier C. (Universidad Europea de Madrid)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	To estimate the prevalence of lower urinary tract symptoms (LUTS) in patients with prostate cancer scheduled to receive LHRH analogs, and to assess the effectiveness of LHRH analogs on LUTS in patients presenting moderate/severe symptoms. Prospective, noninterventional, multicenter study conducted at 28 centers in Spain and Portugal. LUTS were evaluated using the International Prostate Symptom Score (IPSS) at baseline, 24 and 48 weeks after initiation of treatment. Subanalyses were performed according to age and concomitant treatment (radiotherapy, alpha-blockers, and antiandrogens). A total of 354 patients were treated with LHRH analogs for 48 weeks. The percentage of patients with moderate/severe LUTS (IPSS > 7) decreased from 60. 2% (n = 213/354) at baseline to 52. 8% (n = 187/354) at Week 48. Among patients with moderate/severe LUTS at baseline: 73. 7% (n = 157/213) still had moderate/severe LUTS at Week 48; percentage reductions of patients with LUTS at Week 48 were statistically significant (p < 0. 05) overall and by age or concomitant treatment, except for alpha-blockers (84. 2% patients receiving them still had moderate/severe LUTS at Week 48). All IPSS items, including quality of life for urinary symptoms, improved throughout the study. The only predictor of response to treatment with LHRH analogs that improved IPSS by 3 points after 48 weeks was baseline testosterone levels. Lower baseline testosterone levels were associated with greater improvement in IPSS after treatment with LHRH analogs (odds ratio 0. 998, 95% confidence interval 0. 996-1. 000, p = 0. 0277). LHRH analogs have a positive effect in patients with locally advanced or metastatic prostate cancer presenting moderate/severe LUTS regardless of age or concomitant treatment received (radiotherapy, antiandrogens, or alpha-blockers).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Androgen deprivation ; Concomitant ; Hormonal therapy ; Quality of life ; Radiotherapy
Published in:	Neurourology and Urodynamics, Vol. 41 (september 2022) , p. 1824-1833, ISSN 1520-6777

DOI: 10.1002/nau.25031
PMID: 36069170

10 p, 1013.3 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles